Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Gross Margin (2019 - 2025)

Historic Gross Margin for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Q3 2025 value amounting to 84.73%.

  • Catalyst Pharmaceuticals' Gross Margin fell 2900.0% to 84.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 85.68%, marking a year-over-year decrease of 6400.0%. This contributed to the annual value of 86.0% for FY2024, which is 9500.0% down from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Gross Margin is 84.73%, which was down 2900.0% from 85.94% recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Gross Margin high stood at 88.35% for Q1 2023, and its period low was 80.82% during Q4 2021.
  • Moreover, its 5-year median value for Gross Margin was 85.7% (2023), whereas its average is 85.54%.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Gross Margin tumbled by -34800bps in 2021, and later surged by 41300bps in 2023.
  • Catalyst Pharmaceuticals' Gross Margin (Quarter) stood at 80.82% in 2021, then increased by 1bps to 81.57% in 2022, then grew by 5bps to 85.7% in 2023, then dropped by -1bps to 84.74% in 2024, then fell by 0bps to 84.73% in 2025.
  • Its last three reported values are 84.73% in Q3 2025, 85.94% for Q2 2025, and 87.33% during Q1 2025.